OBJECTIVES: Various factors may interact with Diabetes Mellitus (DM) to increase the risk of dementia. This study examined socio-demographic factors, the use of diabetes-specifi c drugs and the duration of DM as risk factors for dementia in elderly DM patients who are eligible to receive care at Veterans Health Administration. METHODS: This was a retrospective study on a national cohort of US veterans. Incident DM elderly ( 65 years) identifi ed between October 1, 1996 and December 31, 2000 in the VA records or between January 1, 1999 and December 31, 2000 in the VA-Medicare merged claims fi les were included for the fi nal analysis. The period prevalence of diabetes-specifi c drugs was determined in Calendar Year (CY) 2000. The time to the incidence of dementia was assessed from CY2001 to CY2002. A multivariable Cox regression model was used to estimate the adjusted relative risk of dementia for various predictors. RESULTS: A total of 377,838 patients were included in the fi nal analysis. Age was a major risk factor for dementia: patients 75-85 years of age, HR 2.09, 95% CI 2.02-2.17; patients 85 years and older, HR 3.47, 95% CI 3.27-3.67. Compared to whites, African Americans had a higher risk of dementia (1.22, 1.16-1.27). People from the southern region of the U.S. had a higher risk of dementia compared to other regions. Oral hypoglycemic agent use was associated with a higher risk of dementia (1.34, 1.29-1.39). The use of HMG-CoA reductase inhibitors was associated with a reduced risk of dementia (0.88, 0.85-0.91). Insulin was not associated with dementia (1.02, 0.98-1.07). The duration of diabetes was an important risk factor for dementia. CONCLUSIONS: This exploratory study provides an important insight into the risk factors for dementia in a large population of DM patients. Additional studies should examine the process and outcomes for patients with these important chronic disease conditions.
PDB13 PATTERNS AND POTENTIAL RISKS OF CO-PRESCRIBING ANTIHYPERGLYCEMICS AND SILYMARIN: A TAIWANESE POPULATION-BASED STUDY
Chan AL 1 , Leung HW 2 , Chien TW 3 1 Chi-Mei Medical Center, Taianan, Taiwan, 2 Chi-Mei Medical Center, Tainan, Taiwan, 3 Chi-Mei Medical Center, Yung Kang, Tainan, Taiwan OBJECTIVES: The aim of this study was to analyze trends and potential risks of combined use of silymarin and hypoglycemic drugs in a Taiwanese population. METHODS: Data for this retrospective and descriptive population-based study were retrieved from the Taiwan National Health Insurance Research Database representing 200,000 sampling benefi ciaries enrolled in the program in the year 2000. The prescription details of ambulatory care orders were retrieved for 2000 to 2006. The extent of co-prescription of silymarin and hypoglycemic drugs and associations with patient characteristics, hospital type, and co-morbid chronic diseases were assessed, including an analysis using the many-faceted Rasch model. RESULTS: Silymarin prescriptions increased from 0.17% (860/515765) in 2000 to 0.76% (2335/309053) in 2006. Silymarin combined with hypoglycemic drugs was mostly prescribed to patients 60 years or older. Among this group, the percentage of prescriptions with silymarin alone increased about four-fold, from 245 in 2000 to 1022 in 2006. The number of co-prescriptions in the same age group also increased in the same period from 11 (15.49%) to 206 (58.8%). Most prescriptions were prescribed for 28 days. Of the combined prescriptions, 42% were prescribed at the same ambulatory care visit. Co-prescription of silymarin and hypoglycemic drugs correlated with patient characteristics, physician specialty, antidiabetic type, and other confounders. CONCLUSIONS: There was a trend to increase of co-prescription of silymarin and hypoglycemic drugs in Taiwan's elderly population from 2000 to 2006. Physicians should take particular care in adjusting the dose of hypoglycemic drugs when prescribing these drugs and silymarin concurrently in this age group.
PDB14 FORECASTING THE NUMBER OF DIABETIC PATIENTS IN THE UNITED STATES THROUGH 2025
Baser O 1 , Wang L 2 1 University of Michigan and STATinMED Research, Ann Arbor, MI, USA, 2 STATinMED Research, Ann Arbor, MI, USA OBJECTIVES: To project the number of people with diagnosed diabetes in the United States through 2025, accounting for changing demography and diabetes prevalence rates. METHODS: We combined age, sex, and race specifi c diabetes prevalence rates -predicted from the 1980-1998 trends in prevalence data from the National Health Interview Survey -with the population projections derived from MEPS. Sensitivity analysis was performed by varying both population projections and prevalence rates. RESULTS: Populations of the number of people with diabetes will rise to almost 18 million in 2025. The largest increases in the number of people with diabetes are likely to occur in the oldest age category. The highest growth will be among black males whereas the lowest increase will be in the white females category. Twenty percent of the overall projected growth will be due to population growth, 35% to an increase in prevalence rate, and 45% to changes in demographic compositions. CONCLUSIONS: This paper shows the projection of dramatic increase of the diabetic population in the United States by 2025. Worldwide surveillance of diabetes is a necessary fi rst step toward its prevention and control.
PDB15 UTILIZATION PATTERNS AND HYPOGLYCEMIA IN PATIENTS WITH TYPE-2 DIABETES ON CONCOMITANT EXENATIDE AND LONG-ACTING INSULIN THERAPY
Wade R 1 , Quimbo RA 2 , Fabunmi R 3 , Blickensderfer AL 3 , Pawaskar MD 4 , Misurski D 4 1 HealthCore, Inc., Wilmington, DC, USA, 2 HealthCore, Inc., Wilmington, DE, USA, 3 Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 4 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: To examine utilization patterns and hypoglycemia in patients with type-2 diabetes mellitus (T2DM) receiving concomitant exenatide and long-acting insulin therapy over 6 months. METHODS: A retrospective analysis was performed using claims data (January 1, 2004 to March 31, 2008 ) from a large US prescription database. Adult patients with T2DM and no claim for exenatide (index drug) in the previous 12 months were included. At least 12 months pre-index and 6 months post-index continuous eligibility were required. Concomitant long-acting insulin use was defi ned as a claim for NPH, insulin glargine or insulin detemir 100 days pre-index to 15 days post-index. Therapy discontinuation was defi ned as a 60 day gap between prescription claims. Hypoglycemic events were identifi ed by ICD-9 codes 250.8, 251.0, 251.1, and 251.2. Hypoglycemia generating a claim using these codes is generally severe. RESULTS: Concomitant exenatide and long-acting insulin use was identifi ed in 2082 patients. Of these, 38% discontinued both therapies, 15% discontinued exenatide but remained on long-acting insulin, 24% discontinued long-acting insulin but remained on exenatide and 23% continued both therapies. There were no differences in age, gender or Deyo-Charleson comorbidity index score among cohorts. Patients who discontinued exenatide and remained on long acting insulin had a higher mean rate of hypoglycemia (0.10 1.01 events/patient/6-months), compared to patients who discontinued long-acting insulin but remained on exenatide (0.02 0.20), discontinued both therapies (0.04 0.37) or continued both therapies (0.03 0.26; p 0.0001 across groups). Insuffi cient pre-and post-A1C values were available for an analysis of this endpoint. CONCLUSIONS: Patients remaining on concomitant exenatide and long-acting insulin did not experience more hypoglycemic events than patients who remained on either drug alone. However, patients discontinuing exenatide but remaining on long-acting insulin experienced signifi cantly more hypoglycemic events. The increase in hypoglycemic events may have been due to an increase in basal insulin dose and/or the addition of other insulin therapy.
PDB16 REPLICATION AND VALIDATION OF THE QUANTIFICATION OF THE RELATIONSHIP BETWEEN PHARMACOLOGIC INTERVENTION, REDUCTIONS IN HBA1C AND REDUCTIONS IN COMPLICATIONS: ITS APPLICATION IN QUANTIFYING THE BENEFITS OF ADDING COLESEVELAM HYDROCHLORIDE TO METFORMIN IN TYPE-2 DIABETICS
Simons WR 1 , Hagan MA 2 1 Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA, 2 Daiichi Sankyo, Inc., Wayne, NJ, USA OBJECTIVES: Quantify the reductions in diabetic related complications associated with the addition of colesevelam hydrochloride to metformin in patients with type-2 diabetes who have not achieved optimal control. METHODS: The quantifi cation of the effects of pharmacologic intervention on glycaemic control in type-2 diabetics and the quantifi cation that improved glycaemic control reduces the risk of diabetic-related complications was measured in the UK, Germany and the USA using Generalized Estimating Equations (GEE) on longitudinal data. The three models quantifi ed that pharmacologic intervention reduced HbA1c by 0.99%, 0.92% and 0.89%, respectively, (P 0.01). The second set of models quantifi ed that a 1% reduction in HbA1c reduced the rate of complications by 0.388%, 0.414% and 0.436% (P 0.01). Using these validated equations, the effi cacy data from a clinical trial comparing the addition of colesevelam hydrochloride to metformin versus metformin alone in type 2 diabetic patients who lack optimal control despite treatment was converted into reductions in the onset new diabetic-related complications. 5000 bootstrap samples of 100 patients from each treatment group were replicated to measure and minimize bias. RESULTS: In the fi rst year, the addition of colesevelam to metformin reduces the number of diabetic related complications by 10,757 in 100,000 type-2 diabetics who lack glycaemic control despite treatment. The most prevalent of those complications are manifestations of neurological dysfunction (0.0166), disorders of the peripheral circulation (0.0170) and ischemic heart disease (0.0178). Treatment with coleselevam in these patients who had not achieved optimal control reduced those events by 1790 neurological disorders, 1829 peripheral circulatory disorders and 1917 new cases of ischemic heart disease. The number of events avoided by year two and three accrued to 18,173 and 27,505 per 100,000 patients. CONCLUSIONS: Effective treatment by adding colesevelam to metformin quantifi ably reduces HbA1c and complications in patients who have not achieved control.
